OBLN Obalon Therapeutics

Obalon Schedules Fourth Quarter and Year-End 2019 Financial Results Conference Call for February 27, 2020 at 8:30 a.m. Eastern Time

Obalon Schedules Fourth Quarter and Year-End 2019 Financial Results Conference Call for February 27, 2020 at 8:30 a.m. Eastern Time

SAN DIEGO, Feb. 13, 2020 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: ), a weight loss solutions company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces that it plans to release its fourth quarter and year-end 2019 financial results before the market opens on Thursday, February 27, 2020 and hold a conference call at 8:30 AM Eastern Time (5:30 AM Pacific Time) to discuss the Company's financial results and provide a business update. Interested parties may access the conference call by dialing (844) 889-7791 (U.S.) or (661) 378-9934 (international) using passcode 6573298. Media and individuals will be in a listen-only mode. Participants are asked to dial in a few minutes prior to the call to register for the event. The conference call will also be webcast live at: .

An archive of the webcast will be available for twelve months following the event on the Obalon Therapeutics website located at in the “News & Events” section. 

About Obalon Therapeutics, Inc.

Obalon Therapeutics, Inc. (NASDAQ:) is a San Diego-based company focused on developing and commercializing novel technologies for weight loss. For more information, please visit .

For Obalon Therapeutics, Inc.

Investor Contact:

William Plovanic

President & Chief Executive Officer

Obalon Therapeutics, Inc.

Office:

EN
13/02/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Obalon Therapeutics

 PRESS RELEASE

Obalon Announces First Quarter 2021 Financial Results

Obalon Announces First Quarter 2021 Financial Results SAN DIEGO, May 12, 2021 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its financial results for the first quarter ended March 31, 2021. On January 19, 2020 the Company signed a definitive agreement for a merger with ReShape Lifesciences Inc. Financial results for the first quarter of 2021 Revenue for the first quarter of 2021 was no...

 PRESS RELEASE

Obalon Announces Fourth Quarter and Full Year 2020 Financial Results

Obalon Announces Fourth Quarter and Full Year 2020 Financial Results SAN DIEGO, March 12, 2021 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its financial results for the fourth quarter and full year ended December 31, 2020. On November 10, 2020, the Company signed a non-binding term sheet for merger with ReShape Lifesciences Inc. and, on January 20, 2021, announced that a definitive agreeme...

 PRESS RELEASE

Obalon Announces Third Quarter 2020 Financial Results

Obalon Announces Third Quarter 2020 Financial Results SAN DIEGO, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its financial results for the third quarter ended September 30, 2020. Financial results for the third quarter of 2020 Revenue for the third quarter of 2020 was $44,000, compared to $0.3 million for the third quarter of 2019, with the decrease primarily due to the sus...

 PRESS RELEASE

Obalon Announces Consulting Agreement As Part of Strategy To Seek Cove...

Obalon Announces Consulting Agreement As Part of Strategy To Seek Coverage and Reimbursement for The Obalon Balloon System SAN DIEGO, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (Nasdaq: OBLN), a weight loss solutions company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced that it has executed a consulting agreement with Blue Ox Healthcare Partners, LLC, a private equity firm focused on commercial-ready companies bringing technology enabled innovation to healthcare, especially those invo...

 PRESS RELEASE

Obalon Announces Second Quarter 2020 Financial Results

Obalon Announces Second Quarter 2020 Financial Results SAN DIEGO, July 30, 2020 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its financial results for the second quarter ended June 30, 2020. Financial results for the second quarter of 2020 Revenue for the second quarter of 2020 was $0.7 million, compared to $0.4 million for the second quarter of 2019, primarily due to reversals of revenue...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch